-
Mashup Score: 0Genomics-guided therapy & multimodal treatment strategy - 4 year(s) ago
James Eastham, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses how genomics is going to markedly change how…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Enfortumab vedotin with pembrolizumab for bladder cancer - 4 year(s) ago
Guru Sonpavde, MD, Dana-Farber Cancer Institute, Boston, MA, outlines his research highlights from the 2020 ASCO GU meeting. Dr Sonpavde…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Hannah Rush joins Alicia Morgans discussing the quality of life outcomes we have seen from patients receiving docetaxel or abiraterone in the STAMPEDE trial. STAMPEDE is a multi-arm, multi-stage trial investigating various therapeutic strategies for the management of locally advanced or metastatic hormone-naïve prostate cancer. In recent years, both docetaxel and abiraterone have been shown to…
Source: UroTodayCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 0Validation of a Prognostic Genomic Classifier in Salvage Radiotherapy Prostate Cancer from a Prospective Randomized Trial - Felix Feng - 4 year(s) ago
Alicia Morgans is joined by Felix Feng to discuss his recent presentation on a new analysis from the Phase III RTOG 9601 trial. They discuss the application of using Decipher, a test based on gene expression profiles in primary tumors in prostate cancer, which adds significantly to identifying the men with the most aggressive disease. It drives the discussion to when we adopt genomic biomarkers…
Source: UroTodayCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 2Radioligand therapy advancements in prostate cancer - 4 year(s) ago
Jeremie Calais, MD, University of California, Los Angeles, CA, outlines advancements in radioligand therapy in prostate cancer, specifically talking on…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0ASCO GU 2020: Current Developments in Rare Urologic Malignancies: Are Biomarkers Going to Change the Future of Testicular Cancer? - 4 year(s) ago
ASCO GU 2020 prognosis of testicular cancer, micro-RNA biomarker targets, miR371, RPLND in the post chemotherapy setting, miRNA as a useful biomarker.
Source: www.urotoday.comCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 0Making Quality Inferences from GU ASCO Quality of Life Data: How I Interpret the Evidence - 4 year(s) ago
measuring quality of life data for patients with prostate cancer, quality of life during treatment with chemotherapy, quality of life data from the CARD trial, quality of life data from the STAMPEDE trial, GU ASCO 2020 quality of life CARD data
Source: www.urotoday.comCategories: Latest Headlines, UrologyTweet-
Making quality inferences from @ASCO #GU20 Quality of Life data: How I interpret the evidence. New #blog by @CaPsurvivorship @NUFeinbergMed providing a detailed understanding of the data from #STAMPEDE & #CARD and how it can be used. #ReadNow on UroToday > https://t.co/X0KryPzjBi https://t.co/1WZstLKNL3
-
-
Mashup Score: 0Association of metagene based on gene expression with response to atezolizumab (atezo) for metastatic urothelial carcinoma (mUC). - 4 year(s) ago
569 Background: Despite the benefits of PD1/L1 inhibitors in metastatic urothelial carcinoma (mUC), the durable benefits accrue mostly to a minority of patients (pts) who attain ≥partial response (PR) by RECIST 1.1. There is a pressing need to identify pts with a low probability of response, who may be diverted to other regimens or trials. Biomarkers associated with response such as PD-L1…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
#bladdercancer #research monthly web meeting @danafarber well attended- talk by @aravi1 @broadinstitute -leveraging gene expression to develop #precisionmedicine-follows recent #GU20 presentation-vital to make progress in #cancer #research despite #COVID19 https://t.co/IKKzR7Ou2f https://t.co/1HaA038zjf
-
-
Mashup Score: 0
Joining Ashish Kamat is Arjun Balar, both experts in the field of bladder cancer and each closely involved with the FDA approval of pembrolizumab in the BCG-unresponsive bladder cancer population. Dr. Balar outlines the history of the drug, how the study which led to the FDA approval in NMIBC was designed. Dr. Balar also expands in his approach to counseling his patients who are considering…
Source: UroTodayCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 0Financial Toxicity and Quality of Life: Understanding and Improving Patient-Centered Outcomes in Genitourinary Malignancies - David Penson - 4 year(s) ago
David Penson provides insights on his keynote lecture from ASCO GU 2020 in this conversation with Alicia Morgans. He focuses on recognizing that methods of effectively measuring a patient’s quality of life are not easy to define. In addition to the physical, psychological and social experiences that contribute to a patient’s quality of life, Dr. Penson argues the growing burden of financial…
Source: UroTodayCategories: UrologyTweet-
Financial toxicity and quality of life: Understanding and improving patient-centered outcomes in genitourinary malignancies. @urogeek @VUMChealth speaks with @CaPsurvivorship @NUFeinbergMed regarding his keynote lecture @ASCO #GU20. #WatchNow on UroToday > https://t.co/BShqvseiLH https://t.co/GVJj6wmKSs
-
VIDEO: Genomics-guided therapy & multimodal treatment strategy w/ James Eastham of @sloan_kettering: https://t.co/lZJoPVhPMY #GU20 @ASCO @ASTRO_org #UroSoMe #UroOnc #GUsm